Corrigendum to ‘Equivalency challenge: evaluation of Lipodox® as the generic equivalent for Doxil® in a human ovarian cancer orthotropic mouse model’ [Gynecol. Oncol. (2016) 141 (357–363)] (S0090825816300579)(10.1016/j.ygyno.2016.02.033)

The authors wish to correct an inaccurate reference and mis-statement in the above named manuscript, in which the study by Chou and colleagues, cited as reference 14, used a different generic liposomal doxorubicin product called Lipo-Dox® (TTY Biopharm). This product is not the same as the generic liposomal doxorubicin product that was evaluated in the authors’ paper (Lipodox® manufactured by Sun Pharmaceuticals Industries Ltd). The reference to the study carried out by Chou and colleagues was incorrectly cited by the authors and the reference in the article to “multiple” clinical observations that Lipodox® did not appear to be as effective as with Doxil® in recurrent ovarian patients therefore related to one study (cited in the paper as reference 11) rather than two. Reference 14 should have read: H.H. Chou, K.L. Wang, C.A. Chen, L.W. Wei, C.H. Lai, C.Y. Hsieh, Y.C. Yang, N.F. Two, T.C. Chang, M.S. Yen, Pegylated liposomal doxorubicin (Lipo-Dox ®) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow up, Gynecol. Oncol. 101 (2006) 423-428.” The authors apologize for confusion caused by the mis-citation of reference 14 in the paper.